A multivariate plasma biomarker model for glioblastoma exclusion: a retrospective case-control study.
BACKGROUND Glioblastoma (GBM) remains the most aggressive primary brain tumour, with limited diagnostic tools able to capture its molecular heterogeneity in real time. Current clinical practice relies on MRI and invasive biopsies, which are poorly suited for early or dynamic disease monitoring. Sensitive and accessible...